Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Breast Neoplasms: early-phase trial registry
35 of 98 indexed Breast Neoplasms trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #141 of 28,707 conditions by registered trial count.
98 US clinical trials · 35 currently recruiting · #141 of 28,707 conditions by registered trial count
Breast Neoplasms: 98 US clinical trials tracked, 35 recruiting.
Breast Neoplasms is the subject of 98 registered US clinical trials on ClinicalTrials.gov, 35 of them currently open to new participants. 20 are in Phase 3-4 (later-stage) and 51 in Phase 1-2 (earlier-stage). The most active sponsor is Pfizer, running 10 of these trials.
Enrollment posture brief
Registry condition breast-neoplasms
OPEN 35 | RECR 36% | LATE 20 | EARLY 51 | RANK #141 | SPON 10
Volume-matched condition peers
Nearest open-share peer: Acute Respiratory Failure (36% recruiting · 14 trials)
Breast Neoplasms lists 35 open slots (36% of 98 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Breast Neoplasms on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Breast Neoplasms is recruiting below its size-band peers.
35 of 98 indexed trials (35.7%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Breast Neoplasms trials is spread across many organizations.
Pfizer accounts for 10 of 98 trials (10.2%). 60 distinct sponsors appear on at least one study for this condition label.
-
Typical Breast Neoplasms enrolment sits around 134 participants.
Median target enrolment is 134 among the 98 trials that report a genuine target (sentinel values excluded). 40 of those (40.8%) plan for fewer than 100 participants.
-
Breast Neoplasms research is mostly interventional.
85 interventional and 13 observational studies make up this index (86.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
98 total, page 2 of 2
A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
Atavistik Bio
NCT07038369
Multi-Institutional Transgender & Gender-Diverse Breast Cancer Study
Medical College of Wisconsin
NCT06234488
PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer
Washington University School of Medicine
NCT01723774
Study of the Safety of MRI Scans in People Who Have Breast Tissue Expanders After Mastectomy
Memorial Sloan Kettering Cancer Center
NCT04769960
Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast
Icahn School of Medicine at Mount Sinai
NCT03304080
Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer
City of Hope Medical Center
NCT01273610
Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer
US Oncology Research
NCT03379428
A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer
Eisai
NCT04288089
Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer
Providence Health & Services
NCT04373031
Raloxifene Use for The Heart
Eli Lilly and Company
NCT00190593
A Study to Understand About the Study Medicine Palbociclib in Breast Cancer Patients After it is Out in the Japanese Market
Pfizer
NCT07096024
Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer
Intarcia Therapeutics
NCT00044291
Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer
Pfizer
NCT00393939
A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer
Pfizer
NCT00373256
A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
Hoffmann-La Roche
NCT02131064
A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)
Pfizer
NCT01945775
A Study to Determine the Clinical Significance of Molecular Detection of Breast Cancer in the Blood of Stage IV Breast Cancer Patients
Washington University School of Medicine
NCT00355316
Hypnosis to Reduce Aromatase Inhibitor Pain and Improve Adherence
Icahn School of Medicine at Mount Sinai
NCT02657993
AG-013736 In Combination With Docetaxel Versus Docetaxel Alone For Patients With Metastatic Breast Cancer
Pfizer
NCT00076024
Nuevo Amanecer: Promoting the Psychosocial Health of Latinas
University of California, San Francisco
NCT01383174
A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Hoffmann-La Roche
NCT03280563
This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer
Boehringer Ingelheim
NCT03099174
Contrast Enhanced Mammography in Diagnosing Patients With Suspicious Breast Findings
Thomas Jefferson University
NCT03929783
A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)
Ambrx
NCT03255070
Testing of Different Methods for Determining Whether Breast Cancer Has Spread to the Lymph Nodes
Washington University School of Medicine
NCT00360152
Efficacy Study of an Educational Program for Decision Support for Breast Cancer
Baylor College of Medicine
NCT00473096
Study Of The Efficacy And Safety Of SU-014813 In Patients With Metastatic Breast Cancer
Pfizer
NCT00322517
Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors
Novartis Pharmaceuticals
NCT02077933
Bevacizumab Given With Either Anastrozole or Fulvestrant With Trastuzumab for Postmenopausal Metastatic Breast Cancer
SCRI Development Innovations
NCT00405938
Evaluating and Comparing Two Surgical Methods for Treatment of Early Stage Breast Cancer
Emory University
NCT01271738
Using Hyperpolarized [1-13C]Pyruvate to Detect Cardiotoxicity
University of Texas Southwestern Medical Center
NCT03685175
Use of Dynamic Contrast-Enhanced Magnetic Resonance Imaging to Assess Tumor-Associated Vasculature in Patients With Metastatic Breast Cancer
National Institute of Neurological Disorders and Stroke (NINDS)
NCT00071357
A Prospective, Randomized, Phase III Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy With GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) Versus PIXY 321 in Advanced Breast Cancer
National Cancer Institute (NCI)
NCT00001338
Phase 2 Study of TLK286 in Metastatic Breast Cancer
Telik
NCT00035841
Vaccination of High Risk Breast Cancer Patients
University of Arkansas
NCT02229084
Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast Cancer
Georgetown University
NCT00073073
Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen
Sanofi
NCT01042925
Enzastaurin For Breast Cancer Patients Who Previously Received an Anthracycline and a Taxane Chemotherapy
Eli Lilly and Company
NCT00386087
Know Your Risk: Assessment at Screening for Breast Cancer - Pilot Study
Columbia University
NCT02954900
Treatment Patterns and Clinical Outcomes Among Talazoparib-Treated Adults With HER2-Negative mBC With gBRCA1/2m
Pfizer
NCT05141708
PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)
Pfizer
NCT00043368
Phase II Study to Evaluate Tariquidar (XR9576), a Selective MDR-1 Inhibitor, in Chemotherapy Resistant Advanced Breast Cancer
QLT
NCT00048633
Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast Cancer
Boehringer Ingelheim
NCT01325428
Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer
Pharmacyclics
NCT00120939
Ultrasound Targeting for the Lumpectomy Cavity
University of Iowa
NCT00583843
Bright Light on Fatigue in Women Being Treated for Breast Cancer
Washington University School of Medicine
NCT02658708
Studying Normal Breast Tissue and Cancer Risk
National Cancer Institute (NCI)
NCT00341692
Evaluating the T Cell Response to a Peptide-based Vaccine in Patients With Breast Cancer
Craig L Slingluff, Jr
NCT00892567
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 29 |
| Phase 2 | 22 |
| Phase 3 | 19 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Breast Neoplasms records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Breast Neoplasms trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Breast Neoplasms page
98 registered trials, 35 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 35 Breast Neoplasms trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Pfizer sponsors the most Breast Neoplasms trials on record, review their full trial history before evaluating a specific study. See Pfizer's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Breast Neoplasms condition card totals 98 registered trials; most-linked intervention Anastrozole; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.